A Phase I Study of Allogeneic Mesenchymal Stem Cell Therapy in Patients with Heart Failure Secondary to Anthracycline-induced Cardiomyopathy: The Cctrn Stem Cell Injection in Cancer Survivors (Seneca) Trial

Anthracycline-induced cardiomyopathy (AIC) can be irreversible with a poor prognosis, and disproportionately affects women and young adults. Administration of allogeneic bone marrow-derived mesenchymal stromal cells (allo-MSCs) is a promising approach to heart failure treatment. Allo-MSCs are known to favorably affect fibrosis, apoptosis, and inflammation, which are key features of AIC.

Source: Journal of Cardiac Failure - September 30, 2020 Category: Cardiology Authors: Roberto Bolli, Emerson C. Perin, James T. Willerson, Phillip C. Yang, Jay H. Traverse, Timothy D. Henry, Carl J. Pepine, Raul D. Mitrani, Joshua M. Hare, Michael P. Murphy, Joao A. Lima, Adrian P. Gee, Doris A. Taylor, Dejian Lai, Ray F. Ebert, Barry R. D Tags: 276 Source Type: research